Korean Post Marketing Surveillance for ELREXFIO (Elranatamab).

Active, not recruitingOBSERVATIONAL
Enrollment

150

Participants

Timeline

Start Date

June 5, 2025

Primary Completion Date

January 31, 2030

Study Completion Date

January 31, 2030

Conditions
Multiple Myeloma
Interventions
DRUG

Elranatamab

According to the approved label, the recommended doses are step-up doses of 12 mg on day 1 and 32 mg on day 4, followed by a full treatment dose of 76 mg weekly from week 2 to week 24. For patients who have received at least 24 weeks of treatment and have achieved a response, the dosing interval should transition to an every two week schedule.

Trial Locations (1)

Unknown

Pfizer, Seoul

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY